GT Biopharma, Inc.
GTBP
$5.98
$0.7414.13%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 12.16% | -406.74% | -333.75% | -206.37% | -235.84% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -36.14% | 32,656.83% | 8,011.58% | 15,046.77% | 306,333.33% |
| Change in Net Operating Assets | 886.58% | -17.86% | -211.11% | -2,653.85% | 142.94% |
| Cash from Operations | -38.43% | -20.44% | -0.08% | 8.99% | 11.01% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -99.99% | -100.00% |
| Cash from Investing | -- | -- | -- | -99.99% | -100.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 377.28% | 51.92% | 84.68% | -64.65% | -64.65% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | 72.16% | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 118.07% | 449.53% | 430.07% | 151.01% | 118.18% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 93.20% | 1,191.14% | -3.51% | -200.70% | -160.60% |